Recent news on Neulasta

Royalty Pharma Acquires a Portion of New York University's Royalty ...  -  May 4, 2007
PR Newswire (press release),...of approximately 80% of Memorial Sloan Kettering's US and international royalty interests in Neupogen(R) and Neulasta(R) for over $400 million.

Cleveland BioLabs Protectan CBLB612 Produces Breakthrough In Bone ...  -  May 22, 2007
Medical News Today (press release),This compares to the current clinical practice of administering a single purified cytokine, such as G-CSF (Neupogen(R), Granocyte(R), Neulasta(R)).

Novel Developments at Neose  -  May 21, 2007
Motley Fool...in excess of $15 billion -- dominated by Johnson & Johnson's (NYSE: JNJ) Procrit and Amgen's (Nasdaq: AMGN) Aranesp, Epogen, Neulasta, and Neupogen.

Amgen: Still a Bargain Despite Recent Selloff  -  May 14, 2007
Seeking Alpha,The company's principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN,

Amgen Has Morphed Into a Bargain  -  May 2, 2007
Barron's (subscription)And the infection fighter Neupogen and the newer Neulasta added $3.9 billion. But under Chief Executive Kevin Sharer, Amgen has labored to expand its drug

Pricking For Success  -  Apr 29, 2007
Financial Express,...who have taken existing small molecule of complex biologicals and re-formulated them into drug deliveries like Neulasta, PEG-Intron, Lupron depot,

Research and Markets: In 2005, Sepracor's New Insomnia Drug ...  -  Apr 27, 2007
PharmaLive.com (press release),Between 2001 and 2005, the leading new drug launch by first year sales was Amgen's Neulasta (pegfilgrastim) with US$722 million, followed by Genentech/

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  26 Apr 2007
Genetic Engineering News (press release),...of approximately 80% of Memorial Sloan Kettering's US and international royalty interests in Neupogen(R) and Neulasta(R) for over $400 million.

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  26 Apr 2007
Business Wire (press release),...acquisitions of approximately 80% of Memorial Sloan Kettering’s US and international royalty interests in Neupogen® and Neulasta® for over $400 million.

Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 ...  -  Apr 24, 2007
PharmaLive.com (press release),Combined sales of Neulasta and NEUPOGEN in the United States were $777 million in the first quarter of 2007 versus $688 million in the first quarter of 2006

Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 ...  -  Apr 23, 2007
Genetic Engineering News (press release),Combined sales of Neulasta and NEUPOGEN in the United States were $777 million in the first quarter of 2007 versus $688 million in the first quarter of 2006

CoGenesys begins research on infection drug  -  Mar 28, 2007
Pharmaceutical Business ReviewNeulasta, manufactured by Amgen, is currently the only long-acting G-CSF product presently approved in the world. Serious infections and hospitalization can

Cancer fails to slow Joe Franz  -  Apr 2, 2007
Siftings Herald,..."The next morning, I got a shot of Neulasta and went to work." Neulasta is a drug that helps stimulate bone marrow to make white blood cells to help fight

Amgen earnings on the rise as Aranesp sales still grow  -  Apr 24, 2007
Pharma Times (subscription),As for its other drugs, Neupogen (filgrastim) and Neulasta (pegfilgrastim), used to boost white blood cells in patients on chemotherapy, saw combined sales

Cleveland BioLabs Protectan CBLB612 Demonstrates Efficacy In ...  -  Apr 21, 2007
Medical News Today (press release),...of hematopoietic stem cells in blood is multiple injections of granulocyte-colony stimulating factor or G-CSF (Neupogen(R), Granocyte(R), Neulasta(R)).

Keeping the atmosphere — and the mind — calm  -  Apr 18, 2007
Ithaca Journal,These items are adorned with zippy company drug names like “Anzemet (dolasetron mesylate injection/tablets),� “Neulasta (pegfilgrastim),� “Sanofi Aventis,�

Stem Cell Transplants not Superior to Intensive Adjuvant Therapy ...  -  Apr 17, 2007
Cancer Consultants (press release),The current data suggests that a single high-dose regimen supported by stem cells is not superior to sequential Neupogen or Neulasta® supported therapy for

Innovative Pulmonary & PEGylation-based Therapeutic Product ...  -  Apr 14, 2007
Medical News Today (press release),...additional approved partnered products in the US or Europe today, including Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),That's not a worry for Amgen, whose second-generation versions of these industry staples, Aranesp and Neulasta (darbepoetin alfa and PEG-filgrastim,

Tuesday Newspaper Review - Irish Business News and International ...  -  Apr 17, 2007
FinFacts Ireland,Its biggest new products since then, Aranesp and Neulasta, were modifications of the original two. And its other big product, the rheumatoid arthritis drug

BioGeneriX and Neose Announce Initiation of 2nd Phase I Clinical ...  -  Mar 21, 2007
PipelineReview.com (press release),Interim results from the ongoing Phase I clinical trial show a dose-dependent response for GlycoPEG-GCSF versus Neulasta with no reported serious adverse

BioGeneriX and Neose Technologies trial neutropenia drug  -  Mar 22, 2007
Pharmaceutical Business Review...subcutaneously administered, fixed dose of GlycoPEG-GCSF versus the approved fixed dose of Amgen's Neulasta, the only currently marketed long-acting

Biotech Day In Review: BioSimilar Cancer Drug Enters Trial  -  Mar 22, 2007
Seeking Alpha,...which will be compared to Amgen’s (AMGN) Neulasta, the only currently approved long-acting granulocyte colony stimulating factor [GCSF].

Roche Ending Maxygen Deal For Factor VII Over De-Risk'  -  Mar 14, 2007
BioWorld Online,...based Amgen Inc.'s Neulasta (pegfilgrastim), noted analyst Michael King with Rodman & Renshaw in New York, who maintains an "outperform" rating on Maxygen

Nektar Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG ...  -  Mar 14, 2007
PipelineReview.com (press release),...is used in eight approved products in the US and/or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Prescription Drug Sales in USA +8% in 2006 to $275 Billion ...  -  Mar 10, 2007
Think & Ask,Amgen’s Enbrel® rose 12 percent to $3.1 billion, and Amgen’s Neulasta® climbed 28 percent to $2.9 billion. Major cancer-fighting therapies also realized

IMS Health Reports 8.3% Growth In US Prescription Sales For 2006 ...  -  Mar 8, 2007
Trading Markets,Also, Enbrel, another product of Amgen, recorded a 12% increase in sales to 3.1 billion, while sales of Neulasta, also an Amgen product, surged 28% to $2.9

Manhattan Research Reveals Top Consumer-Ranked Pharmaceutical ...  -  Mar 6, 2007
PR Newswire (press release),Glucophage XR, Humira, Humulin, Imitrex, Lamisil, Lantus, Levaquin, Levitra, Lexapro, Lipitor, Lunesta, Nasacort, Nasonex, Neulasta, Neurontin, Nexium,

Amgen Drugs Linked to Leukemia  -  Feb 7, 2007
Red Herring,However, many analysts feel that negative reactions about the prospects for Neupogen and Neulasta are too alarmist. They point out that, while white blood

Generic biotech drugs urged  -  Jan 28, 2007
Baltimore Sun,Volinsky, a 69-year-old resident of Timonium, has had three Neulasta shots and will have at least one more. It is helping his immune system recover from

Cell Therapeutics to create spin-off  -  Feb 12, 2007
Pharmaceutical Business Review...therapeutic proteins and provide a potentially less expensive, streamlined development pathway for next generation biologics like Neulasta or Aranesp.

Cell Therapeutics plans spin-off  -  Feb 12, 2007
Reuters...said it hopes will lower the cost for developing next-generation biologics, such as chemotherapy-related treatment Neulasta or anemia drug Aranesp.

CTI Creates Spin-off to Enhance Biopharmaceutical Development  -  Feb 12, 2007
Genetic Engineering News (press release),...and provide a potentially less expensive, streamlined development pathway for next-generation biologics like Neulasta or Aranesp,� adds Dr. Bianco.

Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth  -  Jan 26, 2007
BioWorld Online,31, driven by growth in the company's top-selling drugs, including Aranesp, Neulasta, Neupogen and Enbrel. Full-year revenues reached $14.3 billion.

Dose-intensive Chemotherapy Improves Survival for Patients with ...  -  Feb 2, 2007
Cancer Consultants (press release),To counter these potentially life-threatening side effects, agents such as Neulasta® (pegfilgrastim) or Neupogen® (filgrastim) are often used.

Business Intelligence Provider Hoover’s Releases Latest Edition of ...  -  Feb 11, 2007
Newswire Today (press release),The numbers were supported by strong sales of anti-anemia drugs Aranesp and EPOGEN, as well as Neulasta and NEUPOGEN, which boost white blood cells in

Dole supports leafy greens marketing pact  -  Feb 7, 2007
Ventura County Star (subscription),Thousand Oaks-based Amgen Inc. makes two of these drugs, Neupogen and Neulasta. The study found that risk for developing the blood conditions was very small

Brain study offers clues into why humans do good  -  Jan 30, 2007
Asbury Park Press,While G-CSF — known by the trade names Neupogen, Neulasta and Granocyte — had a strong effect in mice, early research in cancer patients treated with G-CSF

Amgen Shares Slide 4.5 percent  -  Jan 26, 2007
Red Herring,Some observers noted Amgen has been successful in getting patients to switch to newer anemia drugs Neulasta and Aranesp, whose patents don’t expire until

Critical new drugs won't be made here  -  Jan 27, 2007
Kalamazoo Gazette,The same company produces NeuLasta, which had sales of $3.9 billion last year, and is a drug that stimulates the production of white cells in the body.

Sprycel® Superior to High-Dose Gleevec for Gleevec-Resistant CML  -  18 Jan 2007
Cancer Consultants (press release),...the main side effect of Sprycel was cytopenias that could be corrected by the administration of Neupogen® (filgrastim) or Neulasta® (pegfilgrastim).

Early Use of Neulasta Reduces Complications from Neutropenia in ...  -  Jan 5, 2007
Cancer Consultants (press release),According to results recently presented at the 2006 annual meeting of the American Society of Hematology, the use of Neulasta® (pegfilgrastim) during the

Kepivance® May Decrease Oral Mucositis Following High-dose ...  -  Jan 10, 2007
Cancer Consultants (press release),Researchers from Germany reported the results of combining Kepivance and Neulasta® (pegfilgrastim) in patients with multiple myeloma receiving high-dose

Kepivance® May Decrease Oral Mucositis Following High-Dose ...  -  Jan 8, 2007
Cancer Consultants (press release),Researchers from Germany reported the results of combining Kepivance and Neulasta® (pegfilgrastim) for the prophylaxis of patients with multiple myeloma

Low Incidence of Neutropenic Complications Among NHL and HL ...  -  Jan 3, 2007
Cancer Consultants (press release),Single dose Neulasta has been found to be effective in accelerating neutrophil recovery and prevent febrile neutropenia in a variety of chemotherapy

CoGenesys Files To Begin Clinical Trials Of Neugranin For The ...  -  Jan 5, 2007
Medical News Today (press release),In the second phase, patients will be given chemotherapy prior to dosing with Neugranin, while a positive control group will receive Neulasta(R),

Cancer therapy may weaken bones  -  Jan 12, 2007
United Press International...animal bone density after an eight-day course of treatment with the growth factor, marketed under the trade names of Neupogen, Neulasta and Granocyte.

CoGenesys moves drug into clinical trials  -  Jan 3, 2007
Bizjournals.com,It will compare those results to those from patients it will dose with Neulasta, a rival product from California-based Amgen that was approved by the Food

Research and Markets: Gain an Insight into the Financial ...  -  Dec 20, 2006
PharmaLive.com (press release),Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony

Continence program for women  -  Jan 16, 2007
Belleville News-Democrat,G-CSF is known by the trade names Neupogen, Neulasta and Granocyte. St. Louis Children's Hospital has jumped from 10th to 7th in the latest rankings of the

Pharma Sector: Few Newsmakers Of The Week - Schwarz Pharma ...  -  Jan 6, 2007
Trading Markets,Amgen's Neupogen and Neulasta and Schering AG's Leukine are the only three products approved for marketing in the United States for decreasing the incidence

Cleveland BioLabs Protectans Technology Yields Stem Cell Research ...  -  Jan 11, 2007
Medical News Today (press release),...or mobilized peripheral blood harvesting, is an injection of granulocyte-colony stimulating factor or G-CSF (Neupogen(R), Granocyte(R), Neulasta(R)).

Cleveland Biolabs Stock Moves On Stem Cell Report  -  Jan 10, 2007
Cleveland Leader,...marrow or mobilized peripheral blood harvesting, is an injection of granulocyte-colony stimulating factor or G-CSF (Neupogen®, Granocyte®, Neulasta®).

Sprycel® Superior to High-dose Gleevec® for Gleevec-resistant CML  -  Jan 9, 2007
Cancer Consultants (press release),The main side effect of Sprycel was low levels of blood cells, which may be partly corrected with the use of Neulasta. The researchers concluded that

Research and Markets: Gain an Insight into the Financial ...  -  Dec 20, 2006
Business Wire (press release),Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony ...

Bid to block Amgen drug discount fails  -  Nov 23, 2006
Los Angeles Times,...& Johnson's Ortho Biotech unit claims that Thousand Oaks-based Amgen unfairly bundles Aranesp with its white blood cell-boosting drug Neulasta to cancer ...

Analyst Note: Amgen  -  Nov 24, 2006
MSN Money...biotech unit to block rebate contracts that encourage doctors to use the anemia treatment Aranesp when they use Neupogen or Neulasta, two Amgen drugs used to ...

J&J loses injunction against Amgen  -  Nov 23, 2006
Pharmaceutical Business ReviewAmgen currently offers Aranesp at a discount price when it is bought as package with the drugs, Neupogen and Neulasta, which are designed to boost white blood ...

Zacks Analyst Blog Highlights: Techwell, Sallie Mae, Amgen and ...  -  Dec 6, 2006
Business Wire (press release),...therapeutics. The company’s key products are Epogen/Aranesp (anemia), Neupogen/Neulasta (neutropenia), and Enbrel (inflammatory disease). ...

Concurrent Chemotherapy, Twice-Daily Radiation and Consolidation ...  -  Nov 27, 2006
Cancer Consultants (press release),Side effects of this regimen could probably be decreased with the use of Neupogen® or Neulasta®. Reference: Saito H, Takada Y, Ichinose Y, et al. ...

J.& J. Loses Injunction Bid  -  Nov 22, 2006
New York Times,...offering discounts to cancer clinics that bundled Aranesp purchases with two Amgen drugs for stimulating the growth of white blood cells, Neulasta and Neupogen ...

J&J request for injunction against Amgen is denied  -  Nov 22, 2006
Providence Journal,...offers cancer clinics discounts if they purchase certain amounts of Aranesp and two other Amgen chemotherapy-related drugs, Neupogen and Neulasta, which are ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional